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Background/Aims: Propofol induced sedation with bispec-
tral index (BIS) monitoring has been reported to lead to 
higher satisfaction in patients and endoscopists during endo-
scopic submucosal dissection (ESD) procedures. There are 
no data, however, regarding the efﬁ  cacy of midazolam and 
meperidine (M/M) induced sedation with BIS monitoring dur-
ing ESD. The purpose of this study was to evaluate whether 
M/M induced sedation with BIS monitoring could improve 
satisfaction and reduce the dose of M/M required during 
ESD. Methods:  Between September 2009 and January 
2010, 56 patients were prospectively enrolled and randomly 
assigned to a BIS group (n=28) and a non-BIS group (n=28). 
Patient and endoscopist satisfaction scores were assessed 
using the visual analog scale (0 to 100) following the ESD. 
Results: The mean satisfaction scores did not significantly 
differ between the BIS and non-BIS groups (92.3±16.3 
vs 93.3±15.5, p=0.53) or endoscopists (83.1±15.4 vs 
80.0±16.7, p=0.52). Although the mean meperidine dose 
did not differ (62.5±27.6 vs 51.0±17.3, p=0.18) between 
the two groups, the mean dose of midazolam in the non-BIS 
group was lower than in the BIS group (6.8±2.0 vs 5.4±2.1, 
p=0.01). Conclusions: BIS monitoring during ESD did not 
increase the satisfaction of endoscopists or patients and did 
not lead to an M/M dose reduction. These results demon-
strate that BIS monitoring provides no additional beneﬁ  t to 
M/M induced sedation during ESD. (Gut Liver 2011;5:160-
164)
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INTRODUCTION
Recently, endoscopic submucosal dissection (ESD) has been 
widely used for the resection of early gastric cancers and gastric 
adenomas. ESD is useful for complete histological evaluation of 
the tumor as well as curative resections because of the en bloc 
resection.
1 Although ESD is less invasive and safer method than 
surgery,
2-4 it is a technically difficult procedure; it has a higher 
incidence of complications and requires a longer operation 
time than conventional endoscopic mucosal resection (EMR). 
Therefore, ESD must require the appropriate sedation of patients 
without increasing complications.
The bispectral index (BIS) value is based on a calibrated 
number on the electroencephalograph of the frontal cortex cor-
responding to varying levels of sedation, ranging from 0 to 100 
(0, no cortical activity or coma; 40 to 60, unconscious; 70 to 90, 
varying levels of conscious sedation; 100, fully awake).
5,6 
BIS monitoring has been used to minimize complications 
that may occur during sedation and to evaluate by objective 
measures the level of sedation instead of using the conventional 
measures such as Modified Observer’s Assessment of Alertness 
and Sedation (MOAA/S).
7-9 There were temporal correlations be-
tween BIS levels and MOAA/S scores in previous studies.
6,10,11 
Although several studies showed no clinical role of BIS moni-
toring during endoscopic sedation,
12,13 BIS monitoring during 
ESD procedures with the propofol induced sedation lead to 
higher satisfaction scores among patients and endoscopists.
14 
Propofol has several advantages with regard to maintaining 
deep sedation and reducing patient anxiety, as well as pain and 
discomfort during the procedure.
15,16 Recently, the number of 
gastroenterologists administering propofol directly for endo-
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scopic sedation is increasing, and several studies showed the 
safety of administering propofol by endoscopist.
17,18 However, 
the indications of propofol for sedation in various countries 
still imply that it should be used only by anesthesiologists or by 
intensive-care specialists owing to the narrow therapeutic effect 
of propofol.
19 Instead of propofol, other sedative drugs such as 
midazolam and meperidine are safe and useful for diagnostic 
and therapeutic endoscopy without assist of anesthetics or in-
tensive-care specialists for supervision. Midazolam with meperi-
dine is more frequently used wherever anesthesiologists are not 
available. However, midazolam with meperidine have a longer 
half-life than propofol and long procedure during ESD could 
be at high risk of accumulation of the drugs. Therefore, we 
performed a randomized prospective study to evaluate whether 
BIS monitoring during sedation induced by midazolam and 
meperidine could improve the satisfaction of the endoscopists 
and patients and reduce the dose of drugs. We also evaluated 
the efficacy of the BIS monitor in preventing adverse effects of 
sedation during ESD procedure.
MATERIALS AND METHODS
1. Patients
From September 2009 and January 2010, we prospectively 
enrolled 56 patients who were randomized to BIS group (n=28) 
or non-BIS group (n=28). ESD was performed for gastric adeno-
mas, differentiated-type gastric cancers greater than 30 mm in 
diameter without ulceration and gastric cancers up to 30 mm 
with ulceration, or minute submucosal invasion. Patients were 
excluded if they were under 18 years of age, had an ASA clas-
sification of 4 to 5, were pregnant, had a history of stroke or 
an allergy to sedative drugs. This protocol was approved by the 
Institutional Review Board at Samsung Medical Center.
The sample size was calculated as the difference in the satis-
faction score (0 to 10) of more than two points between the BIS 
group and non-BIS group. Assuming a standard deviation of 
patients satisfaction between the BIS group and non-BIS group 
as 1.87 and 3.03, respectively, each group required 28 patients (ά
=0.05, power=80%). Sixty lesions in 56 patients were included. 
All of the study patients were randomly divided into one of two 
groups by the SPSS program (SPSS Inc., Chicago, IL, USA). The 
level of sedation in the BIS group was monitored using BIS, and 
the level of sedation in non-BIS group was monitored using 
MOAA/S. 
The ESD procedure was performed by one experienced thera-
peutic endoscopist (Jae J. Kim). Blood pressure, heart rate, oxy-
gen saturation, and the depth of sedation were checked using 
standard monitoring systems during procedure. All parameters 
were recorded every three minutes and the time of all events 
was recorded in two groups. The patients and endoscopist could 
not watch the BIS monitoring during the procedure. The assis-
tant could not see the BIS score during ESD procedure in non-
BIS group. The score for satisfaction was obtained from both the 
patients and endoscopist after the ESD and the scores for recall 
of pain during the procedure were recorded. The scores ranged 
from 0 to100 (the lowest score, 0, the highest score, 100), using 
the 100 mm visual analog scale. 
2. Monitoring of alertness and sedation 
MOAA/S scores range from 1 to 5: unresponsive to shaking, 1; 
responsive to shaking only, 2; responsive to normal verbal com-
mands, 3; lethargic but responsive to normal verbal commands, 
4; responsive and alert, 5.
20 The level of sedation with BIS scores 
was defined as follows: >85 (awake), 76 to 85 (moderate seda-
tion), 66 to 75 (deep sedation), and 45 to 65 (general anesthesia). 
The target level of sedation in this study was moderate to deep 
sedation for the ESD. This level was achieved with a score of 2 
or 3 on the MOAA/S and that for the BIS was 65 to 80. 
3. Sedative dosage
The initial intravenous dose of midazolam was 0.03 mg/kg in 
patients less than 60 years of age and 60 kg, 2 mg in patients 
less than 60 years of age and more than 60 kg, and 1 mg in 
patients more than 60 years old. The initial intravenous dose of 
meperidine was 25 mg in patients less than 60 kg, and 50 mg 
in patients less than 60 years old and more than 60 kg. If addi-
tional doses were needed (MOAA/S score ≥4 or BIS score >80), 
midazolam (0.5 to 1 mg) or meperidine (25 mg) was added.
4. Statistical methods
Baseline data from the patients in the two groups were com-
pared by chi-square test or Fisher’s exact test for categorical 
variables. A Student’s t-test for normally distributed continu-
ous variables and a Mann-Whitney test for non-normally dis-
tributed continuous variables were used. For the analysis of a 
correlation between the BIS and MOAA scores, the correlation 
coefficient with repeated observations reported by Bland and 
Altman was used in non-BIS group. Before the analysis, the BIS 
was log-transformed to approximate a normal distribution.
RESULTS
1. Patient characteristics 
Fifty-six patients were enrolled and 6 patients (2 patients in 
BIS group and 4 patients in non-BIS group) were dropped from 
the study because of paradoxical reactions during the proce-
dure. There was no statistical difference in baseline characteris-
tics of the patients between the two groups (Table 1). Although 
the tumor size of the lesions in non-BIS group was smaller than 
in BIS group (p=0.03), there was no statistical difference in the 
resected tumor size, procedure time, and curative resection rates 
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2. Dose of sedative drug and satisfaction score 
The dose of midazolam used in the BIS group was larger than 
in non-BIS group (p=0.01). The mean dose of midazolam and 
meperidine used in BIS group was 6.8±2.0 mg and 62.5±27.6 
mg, respectively. That used in non-BIS group was 5.4±2.1 mg 
and 51.0±17.3 mg, respectively. 
There was no significant difference between the two groups 
with regard to recall of pain during the procedure and satisfac-
tion with sedation (Table 3). Table 4 showed hemodynamic 
parameters, BIS monitoring, and complications. There was no 
blood pressure drop below 90 mmHg during the sedation. The 
mean BIS score in BIS group was lower than in non-BIS group 
(p<0.01). Hypoxemia (SpO2 <90%) was detected in both groups (8 
patients in BIS group and 6 patients in non-BIS group), which 
recovered soon after oxygen was provided. The delayed bleed-
ing and perforation rate did not showed significant difference in 
two scoring system.
We additionally investigated that the correlation of BIS levels 
and MOAA/S scores during ESD procedure because there was 
no data of correlation between two scoring systems in ESD 
procedure. The mean scores of BIS and MOAA/S was 80.1±5.9 
(range, 66 to 98) and 2.8±0.7 (range, 1 to 4), respectively. Two 
scoring systems showed weak correlation in ESD procedure with 
midazolam and meperidine induced sedation (correlation coef-
ficient=0.274, p<0.001). 
DISCUSSION
Several sedative drugs and a variety of combinations such as 
propofol with or without a benzodiazepine or opioid, benzodi-
azepine plus an opioid, a benzodiazepine alone, entonox, and 
others, are used for sedation during endoscopic procedures.
21 
Table 1. Baseline Characteristics of Patients in the BIS and Non-BIS 
Groups
BIS group
(n=26)
Non-BIS group
(n=24)
p-value
Mean age 60.8±10.0 58.3±9.6 0.384
Male:Female 19:7 20:4 0.501
Mean BMI, kg/m
2 23.7±2.7 24.4±2.9 0.696
Concurrent narcotic or 
  anxiolytic medication use
6 (23) 2 (8.3) 0.250
Alcohol   12 (46.2)   5 (20.8) 0.078
Smoking 6 (23)   7 (29.2) 0.623
ASA classification 0.679
  1 17 (65.4) 17 (79.8)
  2   9 (34.6)   7 (29.2)
Data are presented as mean±SD or number (%).
BIS, bispectral index monitoring; BMI, body mass index; ASA, Amer-
ican Society of Anesthesiologists.
Table 2. Endoscopic and Pathological Characteristics of the Two 
Groups
BIS group Non-BIS group p-value
No. of lesions 29 25
Tumors 0.123
  Adenoma   7 (24.1) 11 (44)
  Cancer 22 (75.9) 14 (56.0)
Location 0.838
  Lower 18 (62.1) 14 (56)
  Middle   8 (27.6) 9 (36)
  Upper   3 (10.3) 2 (8)
Resected tumor size, mm 40.3±13.6 40.9±16.1 0.875
Size of lesion, mm 17.6±11.9 11.6±7.6 0.03
Procedure time, min 58.1±29.2 47.0±23.5 0.128
Curative resection 26 (89.7) 22 (88) NS
Data are presented as mean±SD or number (%).
BIS, bispectral index monitoring; NS, not significant.
Table 3. Sedative Drug Doses and Satisfaction Scores of the Two 
Groups
BIS group
(n=26)
Non-BIS group 
(n=24)
p-value
Sedation drug
  Mean dose 
   of midazolam, mg
6.8±2.0 5.4±2.1 0.01
  Mean dose 
   of meperidine, mg
62.5±27.6 51.0±17.3 0.18
Satisfaction score
  Recall of procedure 13.5±28.0 22.5±35.7 0.47
  Pain  12.7±27.4 15.8±30.4 0.97
  Patients 92.3±16.3 93.3±15.5 0.53
  Endoscopist 83.1±15.4 80.0±16.7 0.52
Data are presented as mean±SD.
Recall scores, pain scores, and satisfaction scores range from 0 to 100 
(lowest score, 0; highest score, 100).
BIS, bispectral index monitoring.
Table 4. Hemodynamic, BIS, and Complications
BIS group
(n=26)
Non-BIS group 
(n=24)
p-value
Mean BP, mm Hg 120.9±16.16 119.21±13.46 0.693
Mean heart rate 69.27±14.21 70.46±12.64 0.756
Mean BIS 77.0±2.69 80.3±4.84 <0.01
SpO2 <90%   8 (30.1) 6 (25) 0.649
Electrocautery 1 (3.8) 1 (4.2) NS
Perforation 1 (3.8) 0 NS
Data are presented as mean±SD or number (%).
Mean BP=(2*systolic BP+ diastolic BP)/3.
BIS, bispectral index monitoring; BP, blood pressure; NS, not signifi-
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Propofol has a very rapid onset of action and a short half life; 
it is associated with a fast recovery time from the sedation. 
Several studies have shown that propofol was superior to ben-
zodiazepines and narcotics with regard to rapid induction of 
sedation and fast recovery.
22-25 A recent study showed a higher 
satisfaction with BIS monitoring of propofol induced sedation 
during ESD procedures.
14 However, propofol has a narrow ther-
apeutic range and older patients have an increased sensitivity to 
its effects. In addition, it has no analgesic effects and narcotics 
are required during painful procedures. The combined use of 
narcotics or benzodiazepines can add to the risk of respiratory 
depression caused by unplanned deep sedation and general 
anesthesia. Although propofol induced sedation was safe with 
appropriate monitoring systems, the nurse or endoscopist ad-
ministrated propofol induced sedation is not yet generally rec-
ommended in various countries. 
The combination of midazolam and meperidine for sedation 
without assistance of anesthetics or intensive-care specialists is 
safe and useful. Therefore, we investigated whether midazolam 
and meperidine induced sedation using BIS monitoring affect 
the satisfaction of patients and endoscopist in lengthy and com-
plicated ESD procedure. Contrary to our expectations, the over-
all satisfaction of the patients and endoscopist, the complication 
rate, and the patients’ recall of pain during the ESD procedure, 
did not differ in the comparisons between BIS and non-BIS 
groups. In addition, subgroup analysis of ESD procedure taking 
more than 60 minutes did not showed statistical difference of 
satisfaction of patients and endoscopist. This findings suggest 
that BIS monitoring system for midazolam and meperidine in-
duced sedation during ESD procedure do not give the additional 
efficacy of increasing satisfaction and decreasing complication 
rate. This was consistent with other studies which demonstrated 
that BIS monitoring did not improve any measure of patients 
outcome during endoscopic sedation.
12,13 The midazolam and 
meperidine being used for sedation require 2 to 6 minutes for 
peak effect. Consequently, an under-sedated patient with a BIS 
level of 88 will remain under-sedated. Therefore, the value of 
BIS as an “early warning” sign of patient under sedation is not 
fully appreciated with midazolam and meperidine induced seda-
tion.
We excluded 2 patients in BIS group and 4 patients in non-
BIS group because of paradoxical reaction. Generally, the in-
cidence rate of paradoxical reaction was reported less than 1 
percent during midazolam induced sedation.
26 However, other 
study reported that a lengthy and painful procedure such as 
ERCP was more frequently experienced paradoxical reaction 
because of increased anxiety before performing procedure.
25 The 
high incidence of paradoxical reaction in this study may be as-
sociated with anxiety of patients due to invasive ESD procedure.
Several reports showed temporally significant correlation BIS 
levels and MOAA/S scores.
6,11,27,28 However, there was weak cor-
relation between BIS levels and MOAA/S scores in this study. 
This finding might be induced from the feature of lengthy and 
invasive ESD procedure of our study compared to previous 
reports which included in the simple diagnostic and short dura-
tion of endoscopic procedures.
In this study, the mean dose of midazolam in non-BIS group 
was lower than in the BIS group. This finding might be ex-
plained by the following. First, there was a significant overlap 
of the BIS scores between the deep and moderate levels of seda-
tion. Second, the BIS scores were generally more specific than 
sensitive for the levels of deep sedation, i.e., more sedative drugs 
might be administrated to patients with BIS monitoring even 
with adequate sedation.
11 
Although midazolam and meperidine induced sedation using 
BIS monitoring did not showed efficacy, this was the first study 
to evaluate the usefulness of BIS monitoring with midazolam 
and meperidine induced sedation during ESD procedures. 
In conclusion, the results of this study show that midazolam 
and meperidine induced sedation using BIS monitoring do not 
provide to increase satisfaction of patients and endoscopist, to 
decrease complication rate, and to reduce dose of midazolam 
and meperidine during ESD procedures. Thus, we suggest that 
BIS monitoring does not have additional role in the the mid-
azolam and meperidine induced sedation during ESD procedure.
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